1stOncology™: Cancer Intelligence Service – Page 6386 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

On June 9, 2022 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA) and Aurigene Discovery Technologies Limited ("Aurigene") reported an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target (Press release, Aurigene Discovery, JUN 9, 2022, View Source [SID1234615899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene program. Aurigene will be eligible for up to $60 million in potential clinical development and regulatory milestones and up to $370 million in potential commercial milestones, as well as royalties ranging from the mid-single digits to the low double digits based on annual net sales. During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts. Olema and Aurigene will jointly direct further preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities. Olema continues to be well capitalized with sufficient cash to fund our planned research and development operations into the second half of 2024.

"We continue to have confidence in OP-1250 and its potential to become the endocrine therapy of choice for ER+ / HER2- breast cancer, and believe this collaboration will give us an opportunity to expand our focus on new treatments for cancer in women. Aurigene has an impressive history of successful collaborations and combined with Olema’s deep understanding of cancer biology and extensive development expertise, we believe this is a strong strategic opportunity to enhance our growing discovery portfolio," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.

"This agreement with Olema further validates Aurigene’s proven expertise in discovery and preclinical development of effective cancer therapeutics" said Murali Ramachandra, Ph.D., Chief Executive Officer of Aurigene. "We look forward to the continued development of an Aurigene program, which will now be ably supported by the extensive development capability of Olema."

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

On June 9, 2022 Pfizer Inc. (NYSE: PFE) reported that invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical, at the Storebrand Conference: Invest in the Future on Thursday, June 16, 2022 at 11:40 a.m. CEST (5:40 a.m. EDT) (Press release, Pfizer, JUN 9, 2022, View Source [SID1234615876]).

To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.

The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

I-Mab Alters Collaboration with Ferring Pharma for Developing IBD Candidate

On June 9, 2022 Shanghai I-Mab reported that it will alter its collaboration with Switzerland’s Ferring Pharma to develop olamkicept, a potential therapy for inflammatory bowel disease (Press release, I-Mab Biopharma, JUN 9, 2022, View Source [SID1234615863]). In 2016, I-Mab acquired rights to develop olamkicept. a selective interleukin-6 inhibitor, in Greater China and Korea. Now, Ferring will invest in the global development of olamkicept, while I-Mab will have an option to collaborate with Ferring in olamkicept’s global development at a pre-defined milestone. No details were given, though Ferring mal underwrite a China Phase III trial of olamkicept, and I-Mab will opt into global development later.

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

June 9, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, reported the closing of its rights offering and the final results thereof (Press release, Pulse Biosciences, JUN 9, 2022, View Source [SID1234615850]).

The Company received basic subscriptions and over-subscriptions in excess of the $15 million limit in the rights offering. Available Units were allocated proportionately among those rights holders who exercised their over-subscription right based on the number of Units each rights holder subscribed for under its basic subscription rights, in accordance with the procedures described in the prospectus supplement relating to the rights offering. The remaining oversubscription amounts will be returned by Broadridge Corporate Issuer Solutions, Inc. (the "Subscription Agent") to the investors.

The rights offering resulted in the sale of 7,317,072 units (the "Units"), at a price of $2.05 per Unit, with each Unit consisting of one share of the Company’s common stock, par value $0.001 per share, and one warrant to purchase one share of common stock. The common stock and warrants comprising the Units separated upon the closing of the rights offering and were issued individually. 7,317,072 shares of common stock and warrants to acquire up to an additional 7,317,072 shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the rights offering of $15 million. If exercised, additional gross proceeds of up to $15 million may be received through the exercise of warrants issued in the rights offering. Each warrant is exercisable for one share of the Company’s common stock at an exercise price equal to $2.05. Warrants are exercisable immediately and expire on the fifth anniversary of the closing of the rights offering.

Investors who participated in the rights offering should expect to see the shares and warrants issued to them in book-entry, or uncertificated, form. Shares, warrants and any excess subscription payments are expected to be distributed by the Subscription Agent on or about June 13, 2022.

After giving effect to the issuance of 7,317,072 shares of common stock in the rights offering (but excluding up to 7,317,072 shares of common stock underlying the warrants issued in the rights offering), the Company has 37,119,352 shares of common stock issued and outstanding.

The rights offering was made pursuant to the Company’s shelf registration statement on Form S-3, which became effective on August 21, 2020, the prospectus supplement dated May 4, 2022, and the prospectus supplement dated May 19, 2022, on file with the SEC containing the detailed terms of the rights offering. Subscription rights that were not exercised by 5:00 p.m., Eastern Time, on May 26, 2022, have expired.

Investor Presentation dated June 2022

On June 9, 2022, Moleculin Biotech, Inc. (the "Company") presented the Corporate Presentation (Press release, Moleculin, JUN 9, 2022, View Source [SID1234615849]).